Sulfonylurea-induced inhibition of glucagon secretion from the perfused rat pancreas: evidence for a direct,non-paracrine effect

Summary The effects of sulfonylurea on glucagon secretion were characterized in the perfused rat pancreas using glibenclamide (1 g/ml) or tolazamide (10 g/ml) in the presence of 3.3 mmol/1 glucose. Glucagon release, which was unaffected by glibenclamide at 2.75 mmol/1 calcium, was suppressed at 1.19 and 0.64 mmol/l but transiently stimulated at 0.25 mmol/l extracellular calcium. The insulinogenic effect of glibenclamide at 0.64 and 0.25 mmol/1 calcium was enhanced by 35% and 89%, respectively, compared to the response at 2.75 mmol/1 calcium. The stimulatory effect of the compound on somatostatin secretion, however, was lost at the lower calcium levels. The effects of tolazamide at 2.75 and 0.64 mmol/1 calcium mimicked those of glibenclamide, thus indicating that our results with the latter compound may be representative for all sulfonylureas. In pancreata from insulin-deficient alloxan diabetic rats, glibenclamide completely lost its inhibitory effect on glucagon release at 0.64 mmol/1 calcium. Inhibition was not restored by adding insulin (25 U/1) to the perfusate. However, when diabetic rats had been treated with insulin for 6–7 days, glibenclamide suppressed glucagon release at low calcium levels in the absence of stimulated insulin and somatostatin release. It is concluded that, at low calcium concentrations, sulfonylureas suppress glucagon secretion by a direct action on the A cell and not through paracrine interactions by insulin and somatostatin. Prolonged insulin deficiency impairs the sulfonylurea action on glucagon secretion.